SecSonar.com

Protagonist Therapeutics, Inc. (PTGX)

Protagonist Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Protagonist Therapeutics, Inc. (PTGX) is a Biotechnology company based in US with a market capitalization of $6.4B. Revenue declined 89.4% year-over-year and the company generated $56.1M in free cash flow. This page tracks PTGX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 124 employees · IPO Aug 11, 2016

Valuation

Valuation & price

$102.18 · as of May 17, 2026 · -22.4% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

10.36

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$132$90.75$49.87Jul 25Dec 25Jul 26Jul 7, 25$49.87Jul 9, 25$52.29Jul 11, 25$53.00Jul 15, 25$55.32Jul 17, 25$56.44Jul 21, 25$55.22Jul 23, 25$54.19Jul 25, 25$55.15Jul 29, 25$55.01Jul 31, 25$53.86Aug 4, 25$53.83Aug 6, 25$53.87Aug 11, 25$53.75Aug 13, 25$56.72Aug 15, 25$56.07Aug 19, 25$56.25Aug 21, 25$56.04Aug 25, 25$56.88Aug 27, 25$61.43Aug 29, 25$59.05Sep 3, 25$58.11Sep 5, 25$60.53Sep 9, 25$58.36Sep 11, 25$59.68Sep 16, 25$58.59Sep 18, 25$62.14Sep 22, 25$64.51Sep 24, 25$65.95Sep 26, 25$67.42Sep 30, 25$66.43Oct 2, 25$64.98Oct 6, 25$64.14Oct 8, 25$65.30Oct 10, 25$87.00Oct 14, 25$76.94Oct 16, 25$75.73Oct 21, 25$75.00Oct 23, 25$73.99Oct 27, 25$75.25Oct 29, 25$76.69Oct 31, 25$78.62Nov 4, 25$76.50Nov 6, 25$79.78Nov 10, 25$83.23Nov 12, 25$84.85Nov 14, 25$84.61Nov 18, 25$84.39Nov 20, 25$84.20Nov 25, 25$89.86Nov 28, 25$90.00Dec 2, 25$84.65Dec 4, 25$87.33Dec 8, 25$90.25Dec 10, 25$91.38Dec 12, 25$95.35Dec 16, 25$91.54Dec 18, 25$85.79Dec 22, 25$87.41Dec 24, 25$88.84Dec 29, 25$87.93Jan 2, 26$87.18Jan 6, 26$82.27Jan 8, 26$80.20Jan 12, 26$80.25Jan 14, 26$85.23Jan 16, 26$81.99Jan 21, 26$83.89Jan 23, 26$83.10Jan 27, 26$83.08Jan 29, 26$79.73Feb 2, 26$83.05Feb 4, 26$83.30Feb 9, 26$83.32Feb 11, 26$83.49Feb 13, 26$81.49Feb 18, 26$82.99Feb 20, 26$82.76Feb 24, 26$87.39Feb 26, 26$88.39Mar 2, 26$94.24Mar 4, 26$94.83Mar 6, 26$92.09Mar 10, 26$97.05Mar 12, 26$95.42Mar 17, 26$97.23Mar 19, 26$101.68Mar 23, 26$98.54Mar 25, 26$104.31Mar 27, 26$98.97Mar 31, 26$105.40Apr 2, 26$103.78Apr 7, 26$103.75Apr 9, 26$104.09Apr 13, 26$97.57Apr 15, 26$105.44Apr 17, 26$105.98Apr 22, 26$105.55Apr 24, 26$100.00Apr 28, 26$101.21Apr 30, 26$98.97May 4, 26$99.52May 6, 26$103.97May 8, 26$99.36May 12, 26$99.95May 14, 26$105.55May 18, 26$100.74May 20, 26$100.88May 22, 26$99.19May 28, 26$100.41Jun 1, 26$94.92Jun 3, 26$95.41Jun 5, 26$97.38Jun 9, 26$105.87Jun 11, 26$109.79Jun 15, 26$112.46Jun 17, 26$111.44Jun 22, 26$115.03Jun 24, 26$122.15Jun 26, 26$121.88Jul 2, 26$131.62
$49.7052-week range$131.62
Loading valuation history…

Fundamentals

Key fundamentals

$6.4B

Market cap

-89.4%

Revenue growth (YoY)

97.3%

Gross margin

$56.1M

Free cash flow (USD)

-$557M

Net debt

Net cash position

3.3%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$0.00FY 2017$20.1MFY 2018$30.9MFY 2019$231.0KFY 2020$28.6MFY 2021$27.4MFY 2022$26.6MFY 2023$60.0MFY 2024$434.4MFY 2025$46.0M
$0$46M

Free cash flow by year

2016 → 2025

FY 2016$-30.4MFY 2017$3.2MFY 2018$-50.4MFY 2019$-42.5MFY 2020$-73.0MFY 2021$-109.0MFY 2022$-108.9MFY 2023$-70.8MFY 2024$182.8MFY 2025$56.1M
-$30.4M$56.1M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023100.0%FY 2024100.0%FY 202597.3%
100.0%97.3%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

7

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 5, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $1.1M · 10b5-1 PlanWaddill William D. · Director · $1.1MJun 25, 2026Filing
  • 8-K eventEquity Incentive Plan AdoptedJun 18, 2026Filing
  • Insider sellInsider Sell $969K · 10b5-1 PlanWaddill William D. · Director · $969.1KJun 11, 2026Filing
  • Insider sellInsider Sell $897K · 10b5-1 PlanWaddill William D. · Director · $896.8KJun 1, 2026Filing
  • Insider sellInsider Sell $7.5M · 10b5-1 PlanPATEL DINESH V PH D · Director, President and CEO · $7.5MMay 14, 2026Filing
  • Insider sellInsider Sell $7.5MPATEL DINESH V PH D · Director, President and CEO · $7.5MMay 12, 2026Filing
  • Insider sellInsider Sell $5.9MGiraudo Bryan · Director · $5.9MMay 11, 2026Filing
  • 8-K eventEarnings ReleaseMay 5, 2026Filing
  • Quarterly report10-Q FiledMay 5, 2026Filing
  • Insider sellInsider Sell $185KAli Asif · Chief Financial Officer · $184.6KApr 21, 2026Filing

Questions

Frequently asked questions

What is Protagonist Therapeutics, Inc.'s market cap?

Protagonist Therapeutics, Inc. (PTGX) has a market capitalization of $6.4B.

What is PTGX's P/E ratio?

A meaningful P/E ratio is not available for PTGX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is PTGX's price-to-book (P/B) ratio?

PTGX trades at 10.36 times book value per share.

Are insiders buying PTGX stock?

SEC Form 4 filings show no open-market insider buys at Protagonist Therapeutics, Inc. in the last 90 days (7 sells).

Same arena

Related companies in Biotechnology

RYTM

Rhythm Pharmaceuticals, Inc.

$6.2B

CNTA

Centessa Pharmaceuticals plc

$6.1B

PTCT

PTC Therapeutics, Inc.

$6.1B

KYMR

Kymera Therapeutics, Inc.

$6.7B

TGTX

TG Therapeutics, Inc.

$5.9B

ALKS

Alkermes plc

$7.1B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.